CHAPTER 1

Introduction to drug utilization research

Björn Wettermark1, Monique Elseviers2, Anna Birna Almarsdóttir3, Morten Andersen1, Ria Benko4, Marion Bennie5, Irene Eriksson1, Brian Godman6, Janet Krska7, Elisabetta Poluzzi8, Katja Taxis9, Robert Vander Stichele10 & Vera Vlahovic-Palcevski11

1Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institutet, Sweden
2Centre for Research and Innovation in Care, Faculty of Medicine and Health Sciences, University of Antwerp, Belgium
3Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Denmark
4Department of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Hungary
5Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, United Kingdom
6Department of Laboratory Medicine, Karolinska Institutet, Sweden
7School of Pharmacy, Universities of Greenwich and Kent, United Kingdom
8Pharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Italy
9Department of Pharmacy, Unit of Pharmacotherapy and Pharmaceutical Care, University of Groningen, The Netherlands
10Heymans Institute of Pharmacology, Ghent University, Belgium
11Department of Clinical Pharmacology, University Hospital Center Rijeka, Croatia

KEY POINTS

• Drug utilization research can be defined as ‘an eclectic collection of descriptive and analytical methods for the quantification, the understanding and the evaluation of the processes of prescribing, dispensing and consumption of medicines, and for the testing of interventions to enhance the quality of these processes’.

• The discipline may be seen as the bridge between pharmacoepidemiology and health services research. It is also closely connected to clinical pharmacology, with the principal aim of drug utilization research being to facilitate the safe and effective use of medicines in populations.

• Research in drug utilization began to develop in the 1960s. Some pioneering studies focused on assessing differences in drug utilization between countries or regions. Other studies focused on factors influencing the prescribing patterns of physicians.

• The eclectic nature of drug utilization research requires expertise in a broad range of research methodologies. Part 2 of the book provides guidance on a wide range of quantitative and qualitative methods used in drug utilization research.

• The numerous applications of drug utilization research are illustrated in Part 3, which include sections on comparative drug utilization research, drug utilization and health policy, drug utilization in specific populations and therapeutic areas, determinants of drug utilization, adherence and drug utilization research, the role of drug utilization within the field of pharmacoepidemiology and the assessment and improvement of the quality of medicine use.

Room for improvement in drug utilization

Medicines play an important role in the provision of optimal care and have a major impact on health. During the last decades of the 20th century, new medicines have markedly decreased mortality, shortened hospitalization duration and improved quality of life for millions of people [1,2]. However, it is also important to recognize the negative consequences of drug therapy and the emerging problem of inappropriate drug use, with issues ranging from increased morbidity and mortality to excessive medicalization, polypharmacy, adverse drug reactions (ADRs) and increased antimicrobial resistance.
The economic consequences associated with inappropriate drug use are considerable. The average treatment cost for a single ADR in Germany has been estimated at approximately €2250, equating to €434 million per year [3]. Drug-related hospital admissions have been assumed to account for more than 4% of the total health expenditure in Great Britain [4]. In the United States, the incremental expenditure related to inappropriate use of medicines in the community-dwelling elderly was estimated at $7.2 billion in 2001, and these costs are likely to have increased over time [5]. Other researchers have suggested that for every dollar spent on medications, one additional dollar is needed to correct problems caused by inappropriate use of medicines [6].

The extent of inappropriate use of medicines may be even greater in low- and middle-income countries. Common problems include overuse of drugs such as antibiotics and antidiarrhoeals, polypharmacy and the prescribing of inappropriate drugs (e.g. those with limited efficacy or an uncertain safety profile). In many of these countries, up to 60–80% of health problems are self-medicated and poor adherence to doctors’ prescriptions is common [7].

Medicines are also important from an economic perspective. Internationally, there is increased scrutiny of pharmaceutical expenditures, and medicines have been the most rapidly growing cost component in ambulatory care in most countries [8–13]. Challenges in financing drugs may be an even greater concern in low- and middle-income countries, where medicines can account for up to 60% of total health care spending [14]. The reasons behind the increasing expenditure on medicines include demographic changes, the continued launch of new expensive medicines, rising patient expectations and stricter clinical targets [9,15,16].

**The history of drug utilization research**

The emerging problems of rising expenditure and inappropriate use of medicines clearly demonstrate the need for drug utilization research, a cross-disciplinary and multiprofessional science that aims to describe and understand the use of medicines in society. Research in drug utilization began to develop in the 1960s. The pharmaceutical industry early on expressed the need for drug utilization data that could be used to monitor the performance of its representatives, serve as a basis for marketing and define areas for future drug development and research. This laid the basis for the development of large, commercial databases capable of tracking the prescribing and sales of medicines; Intercontinental Marketing Services (IMS) was one of the pioneers [17]. At the same time, concern about pharmaceutical expenditures stimulated the development of public statistics on drug use, independent of those produced by pharmaceutical companies for marketing purposes. These statistics were initially compiled to allow informed financial, administrative and reimbursement decisions, but they were also valuable for research, assessment of the quality of prescribing and quantification of the risks and benefits of drug use in the population. The extent and nature of these early databases varied substantially between countries; in the beginning, they were mostly based on data collected from wholesalers or health authorities. In recent decades, technical development has facilitated the establishment of large databases in many countries across the world.

The pioneering drug utilization studies in Europe focused on assessing differences in drug utilization between countries or regions [18–21]. Other studies focused on factors influencing the prescribing patterns of physicians [22–24]. In 1969, the World Health Organization (WHO) organized its first meeting on Drug Consumption in Oslo, where researchers expressed the need for a common medicines classification system and for a technical unit of comparison in drug utilization studies [19]. As a result, scientists, mainly from Northern European countries, came together in an informal group and developed a new unit of measurement, initially called the ‘agreed daily dose’, but subsequently named the ‘defined daily dose’ (DDD) [20,21,25]. In 1975, the Norwegian agency Norsk Medisinaldepot published a list of DDDs of medicines registered in Norway, which were classified according to the European Pharmaceutical Market Research Association (EPhMRA) code, with the addition of two chemical subgroups. The invention of the Anatomical Therapeutic Chemical (ATC) classification system and the DDDs enabled cross-national comparisons of drug utilization and was of key importance for the future development of the discipline [25].

In 1976, a small group of scientists active in these areas established the informal Drug Utilisation Research Group (DURG). For approximately 20 years the WHO Regional Office for Europe served as the group’s secretariat, and, consequently, the DURG was often referred as the ‘WHO-DURG’. From 1993, the relationship between the
DURG and the WHO loosened, as the latter was unable to further provide secretarial functions. Consequently, in 1994, an independent European Drug Utilisation Research Group (EuroDURG) interim committee was elected, and, in 1996, at a meeting at Lake Balaton, EuroDURG was formally established [26,27]. The EuroDURG mission stated that drug utilization research should not only provide information on sales of medicines but also facilitate exploration of other questions related to the safe and effective use of medicines, such as:

- Why are drugs prescribed?
- Who prescribes drugs and for whom?
- Do patients take drugs correctly?
- What are the benefits and risks of prescribed drugs?

A number of topics for drug utilization studies have been suggested over the years [27,28], as illustrated in Box 1.1.

Drug utilization research developed quickly and became a common subject at international conferences in clinical pharmacology, pharmacy and epidemiology. Some important milestones and events in the development of drug utilization research are shown in Figure 1.1.

During the 1976 DURG meeting in Copenhagen, it was proposed that the WHO should sponsor a publication on guidelines for performing basic drug utilization studies. At the DURG meeting in 1977, the WHO Regional Office in Copenhagen reaffirmed its interest in publishing such guidelines, and in 1979 the first book was published [21]. A number of other pivotal papers and handbooks have been written throughout the years, describing concepts and methods used in the field [17,29–37]. The issue of prescribing quality has always been an area of interest for drug utilization researchers, and, in 2004, the Drug Utilization Research Quality Indicator Meeting (DURQUIM) was held with the aim of defining a taxonomy, constructing a conceptual framework, examining the validity and discussing the use of prescribing quality indicators [38].

Drug utilization research also developed rapidly outside of Europe. In the United States, the early development of the discipline was largely driven by federal government initiatives, with the purpose of curbing Medicaid expenditures while maintaining quality of care [39]. Further development included the instigation of a number of drug utilization review programmes in various institutions, as well as in ambulatory care [40,41]. Early drug utilization studies were conducted by drug information centres, aimed at increasing awareness of the risks and benefits of new, existing or combined uses of medicines [42,43]. Since 1992, the Agency for Healthcare Research

**Box 1.1** Aspects and consequences of drug utilization to be explored.

<table>
<thead>
<tr>
<th>Medical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benefits: efficacy in preventing, relieving and curing diseases or their symptoms and complications.</td>
</tr>
<tr>
<td>Risks: short-term and long-term adverse effects, special risk factors associated with genetics, disease and environment, nutrition, age, sex, pregnancy, lactation, etc.</td>
</tr>
<tr>
<td>Benefit/risk ratio: the extent to which inappropriate prescribing or use may reduce benefits and increase risks.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Social</th>
</tr>
</thead>
<tbody>
<tr>
<td>Attitudes to drugs and health and their basis: current trends in the ‘drug culture’ versus persistent or resurgent use of traditional medicines.</td>
</tr>
<tr>
<td>Drug abuse and dependence and their causes and trends.</td>
</tr>
<tr>
<td>Improper use of drugs (noncompliance, use of drugs for purposes for which they were not prescribed or recommended): incidence and explanation.</td>
</tr>
<tr>
<td>Discrimination and social injustice (e.g. unavailability of important drugs to those who need them).</td>
</tr>
<tr>
<td>Effect of information and regulatory measures.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Economic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug and product prices and costs; imports versus local production; costs of new drugs versus old drugs and of specialities versus generic products; costs of drug versus non-drug treatment.</td>
</tr>
<tr>
<td>Drug cost/effectiveness/safety ratios for all the comparisons listed above.</td>
</tr>
<tr>
<td>Current and future allocation of national resources (money, personnel, facilities) to the drug and health budget.</td>
</tr>
</tbody>
</table>

*Source: Baksaas and Lunde 1986 [28]. Reproduced with permission from Elsevier.*
Part 1: Introduction

and Quality (AHRQ) has funded drug utilization studies through a collaboration of the Centers for Education and Research on Therapeutics (CERTs). Today, the CERTs programmes conduct research and provide education to advance the optimal use of all therapeutics in order to address the limited comparative information on the risks, benefits and interactions of new and older products and to provide guidance to health professionals on the appropriate and cost-effective use of drugs [44].

In Latin America, a network for drug utilization (LA-DURG) was founded in 1991 at the first meeting of Latin American groups for drug epidemiology, held in Barcelona [45]. Participants at the meeting expressed concern that Latin American drug utilization data were scarce and fragmented across the continent. Local authorities were unable to guarantee the effectiveness and safety of products marketed and had no access to quantitative or qualitative drug utilization data [45].

The few drug utilization studies conducted showed serious problems around the inappropriate prescribing, dispensing and use of medicines. Consequently, the importance of drug utilization research to informing rational drug policy at both national and local levels was recognized.

Drug utilization research also developed in Australia, Asia and Africa [46]. In the early 1990s, the WHO and the International Network for the Rational Use of Drugs (INRUD) published a simple sampling method...
and a standard set of indicators to describe core aspects of prescribing and dispensing [47]. The first International Conference on Improving the Use of Medicines (ICIUM), held in Chiang-Mai, Thailand, in 1997, systematically reviewed the interventions in developing countries [47]. Considerable research gaps in the understanding of safe and effective medicines use were identified, and it was suggested that more research should be directed to promoting the rational use of medicines across multiple settings, including hospitals, the private sector and the community. A number of key areas were also identified for future research, such as interventions to improve the use of antibiotics and antimalarial drugs, methods to assess the impact of drugs and therapeutic committees and the impact of financial incentives on drug utilization patterns.

Over the years, drug utilization research has continued to grow, and a Medline search run in 2015 using the term ‘drug utilization’ gave more than 20000 hits. In addition, several thousand drug utilization studies can be found under other search terms related to the prescribing, dispensing and consumption of medicines. Although there has been an explosion in the availability of data and the development of methods, the research questions raised by EuroDURG in 1969 are still relevant in summarizing the important aims of drug utilization research.

It is also important to acknowledge the commonalities in the development of drug utilization research and pharmacoepidemiology. In 1985, the first International Conference on Linked Databases was held in the United States. The name of the conference was subsequently changed to the International Conference on Pharmacoepidemiology (ICPE), and, in 1989, during the fifth conference in Minneapolis, the International Society for Pharmacoepidemiology (ISPE) was officially launched. Many drug utilization researchers joined the society, and drug utilization studies constituted a large proportion of the presentations at all annual conferences. In 2006, a special interest group in Drug Utilization/Health Service Research (SIG DUR/HSR) was formed within ISPE with the aim of creating a global forum for discussion and cooperation between drug utilization researchers in different continents. EuroDURG merged with ISPE and became the European branch of the special interest group. In 2012, EuroDURG, in collaboration with ISPE SIG DUR/HSR, decided to develop Drug Utilization Research: Methods and Applications for use by researchers, academics and policymakers active in the field.

**Definition and delineation**

In 1977, the WHO defined drug utilization research as ‘studies on the marketing, distribution, prescription and the use of drugs in a society, with special emphasis on the resulting medical, social and economic consequences’ [48]. However, this definition does not fully capture the depth and breadth of drug utilization, and, in 2008, a more extensive one was proposed in the textbook *Pharmacoepidemiology and Therapeutic Risk Management* [37]:

Drug Utilization Research is an eclectic collection of descriptive and analytical methods for the quantification, the understanding and the evaluation of the processes of prescribing, dispensing and consumption of medicines, and for the testing of interventions to enhance the quality of these processes.

Drug utilization research focuses on various medical, social and economic aspects of drug use. Medical consequences include the risks and benefits of drug therapy, while social aspects can be related to inappropriate use. Economic issues deal with the cost of medicines and treatment for patients and society. These areas are described in Box 1.1.

The WHO definition of drug utilization places the research area close to a number of related research fields. The greatest commonality lies with pharmacoepidemiology, which is defined as ‘the study of the utilization and effects of drugs in large numbers of people’ [49]. The main difference between drug utilization research and pharmacoepidemiology is that the latter focuses to a greater extent on the assessment of quantitative risks (and, recently, also benefits) of drug treatment in cohorts of patients, mostly followed in databases. Drug utilization research, on the other hand, focuses on the quantity and quality of medicine use in different countries, regions and settings, and the explanatory factors behind these patterns (Figure 1.2).

Another way to describe the difference between the two research fields has been suggested by Bergman: ‘While drug utilization studies employ various sources of information focusing on drugs, e.g. wholesale and prescription registers, the term “epidemiology” implies that pharmacoepidemiological studies are population based, and link health events to drug exposure’ [50]. Over time, the distinction between the two terms has diminished, and they are sometimes used interchangeably. This interplay between the two fields is illustrated in a bibliometric study on the scope and range of drug...
utilization research abstracts presented at the International Conference on Pharmacoepidemiology [51].

The current definition of drug utilization research illustrates the broad nature of the field, which includes both quantitative and qualitative studies. It also emphasizes that intervention studies aimed at improving drug utilization are an important part of the discipline. Thus, it links drug utilization research to health services research. The latter has been defined as ‘a multidisciplinary field of inquiry, both basic and applied, that examines the use, costs, quality, accessibility, delivery, organization, financing, and outcomes of health care services to increase knowledge and understanding of the structure, processes, and effects of health services for individuals and populations’ [52]. Consequently, drug utilization research may be seen as the bridge between pharmacoepidemiology and health services research (Figure 1.3).

Drug utilization research is also connected to the discipline of clinical pharmacology. Researchers in this field study pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body). The original aims of clinical pharmacology were to develop new medicines and to determine the balance between drug benefit and risk in clinical trials. In recent years, the scope of clinical pharmacology has widened to include exploration of drugs as therapeutic agents and assessment of the beneficial and adverse effects of the use and the deliberate misuse of drugs [53]. Clinical pharmacology has a strong focus on pharmacovigilance activities, such as the reporting, collecting and evaluation of ADRs; however, clinical pharmacologists are also engaged in promoting rational drug use through medical education, drug information centers, therapeutic drug monitoring services and drug and therapeutic committees.

While clinical pharmacology studies the ‘absolute’ efficacy of a drug in clinical trials under ideal conditions, drug utilization research and pharmacoepidemiology study the ‘real-world’ effectiveness of medicines and attempt to identify and quantify risks that are difficult to observe or assess in clinical trials or spontaneous reporting systems. Furthermore, drug utilization research includes assessment of the appropriateness of drug use and expenditure.

There are a number of other scientific disciplines that share relationships with drug utilization research, as shown in Table 1.1. The interplay with some of these disciplines is further described in Part 3, Section G.

---

**Table 1.1**

<table>
<thead>
<tr>
<th>Factors influencing drug utilization</th>
<th>Prescribing, dispensing and consumption of drugs</th>
<th>Outcomes of drug therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient and provider characteristics, disease patterns, marketing, regulations and reimbursement, etc.</td>
<td>Benefits and risks, e.g. mortality, morbidity, hospitalizations, quality of life</td>
<td></td>
</tr>
</tbody>
</table>

**Figure 1.2** Traditional descriptions of drug utilization research and pharmacoepidemiology.

**Figure 1.3** Drug utilization research as a bridge between pharmacoepidemiology and health services research.
<table>
<thead>
<tr>
<th>Discipline</th>
<th>Definition</th>
<th>Commonalities of interest</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical pharmacology</td>
<td>Scientific discipline that involves all aspects of the relationship between drugs and humans. Its breadth includes the development of new drugs, the application of drugs as therapeutic agents, the beneficial and adverse effects of drugs in individuals and society and the deliberate misuse of drugs</td>
<td>Studies of the beneficial and adverse effects of drugs in society</td>
<td>Birkett et al. 2010  [53]</td>
</tr>
<tr>
<td>Clinical pharmacy</td>
<td>Branch of pharmacy in which pharmacists provide patient care that optimizes the use of medication and promotes health, wellness and disease prevention</td>
<td>Drug utilization studies are important tools in optimizing the use of medicines in society</td>
<td>ACCP 2008  [54]</td>
</tr>
<tr>
<td>Health services research</td>
<td>A multidisciplinary field of inquiry, both basic and applied, that examines the use, costs, quality, accessibility, delivery, organization, financing and outcomes of health care services in order to increase our knowledge and understanding of the structure, processes and effects of health services for individuals and populations</td>
<td>Analyses of the use, costs, quality, accessibility, delivery, organization, financing and outcomes of medicines in society</td>
<td>IOM 1995 [52]</td>
</tr>
<tr>
<td>Health technology assessment</td>
<td>Research that systematically examines the short- and long-term consequences, in terms of health and resource use, of the application of a health technology, a set of related technologies or a technology-related issue</td>
<td>Analyses of the medical, organizational, economic and societal consequences of drug utilization</td>
<td>Henshall et al. 1997 [55]</td>
</tr>
<tr>
<td>Outcomes research</td>
<td>Study of the end results of health services taking patients’ experiences, preferences and values into account</td>
<td>Analyses of the outcome of drug therapy for patients and society</td>
<td>Clancy &amp; Eisenberg 1998 [56]</td>
</tr>
<tr>
<td>Pharmacoeconomics</td>
<td>Description and analysis of the costs of drug therapy to health care systems and society</td>
<td>Descriptive and analytical studies of expenditure on medicines</td>
<td>Bootman et al. 2005 [57]</td>
</tr>
<tr>
<td>Phamacoepidemiology</td>
<td>Study of the utilization and effects of drugs in large numbers of people</td>
<td>Descriptive and analytical studies of drug utilization</td>
<td>Strom 2012 [49]</td>
</tr>
<tr>
<td>Pharmacovigilance</td>
<td>The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems</td>
<td>Surveillance of side effects related to the use of medicines</td>
<td>WHO 2002 [58]</td>
</tr>
<tr>
<td>Therapeutic risk management</td>
<td>Strategies to ensure that the benefits of a particular drug outweigh its risks in general practice</td>
<td>Analyses of the appropriate use of medicines and interventions to promote rational use of drugs</td>
<td>Hirst et al. 2006 [59]</td>
</tr>
</tbody>
</table>
Skills needed to be a drug utilization researcher

The eclectic nature of drug utilization research requires expertise in a broad range of research methodologies (Box 1.2).

Given the wide range of methods used and the breadth of research expertise needed in drug utilization research, it is important to recognize the multidisciplinary and multiprofessional nature of the area and the need to involve multiple stakeholders from different perspectives, including health care providers, regulators, payers, pharmaceutical companies and the general public. Furthermore, many studies require input from experts in other disciplines, such as health economists and behavioural scientists.

Areas of inquiry in drug utilization research reflected in this book

The methodology section (Part 2) provides guidance on the wide range of methods used in the field. The principal aim of drug utilization research is to facilitate the understanding...

Box 1.2  Skills needed to be a drug utilization researcher following the definition of drug utilization research.

An eclectic collection of descriptive and analytical methods for the quantification...

• Classification systems (ATC and others)
• Measurement units (DDD, expenditure, prescriptions, etc.)
• Analysis of individual usage patterns (persistence, switching, etc.)
• Biostatistical methods (descriptive statistics, sampling, significance, correlation, regression analyses, etc.)
• Epidemiological study designs (ecological studies, cohort studies, case-control studies, case-crossover studies)
• Epidemiological terminology (prevalence, incidence, exposure, outcome, relative risk, odds ratio, bias, confounding, etc.)

...the understanding...

• Qualitative methods (in depth interviews, focus group discussions, observations, etc.)
• Purposive sampling and triangulation
• Approaches to the generation and analysis of qualitative data (phenomenology, grounded theory, qualitative content analysis and narrative analysis, etc.)
• Consensus methods (Delphi and nominal group techniques, consensus development conferences)

...and the evaluation...

• Evaluation techniques
• Single user-focused evaluation versus scientific research evaluation
• The four hierarchical levels of evaluation, including the measurement of reactions to, learning from, behaviour towards and results of interventions (Kirkpatrick's evaluation model)

...of the processes of prescribing, dispensing and consumption of medicines...

• Content and validation of databases derived from medical records or pharmacy dispensing systems
• Data collection from patients (questionnaires, interviews, electronic monitoring devices, etc.)
• Prescribing and reimbursement regulations
• Principles of clinical pharmacology (rational use of drugs, guidelines, critical drug evaluation, etc.)

...and for the testing of interventions...

• Implementation research (how to design and carry out interventions)
• Quasiexperimental study designs (controlled before-and-after studies, time series analyses)
• Cluster randomized trials

...to enhance the quality of these processes

• Quality standards for the prescribing, dispensing and consumption of medicines
• Quality assessment tools
• Quality indicators (terminology, requirement, validation, use, etc.)
• Development techniques for successful interventions and implementation programmes
safe and effective use of medicines in populations. This may be achieved in a variety of ways. Descriptive drug utilization studies can be used to stimulate discussions on potential over- or underuse of medicines. Prescribing patterns may be compared with current recommendations and guidelines to identify areas for improvement. Analytical studies may be conducted to explore factors potentially influencing patterns of drug prescribing, dispensing or consumption. Qualitative studies are also needed to gain an understanding of the perceptions of prescribers, pharmacists and patients.

The applied drug utilization research sections (Part 3) are designed to illustrate recent developments in drug utilization research from different perspectives. The chapters are grouped under the following headings:

- **Section A: Comparative drug utilization research**
- **Section B: Drug utilization and health policy**
- **Section C: Drug utilization in specific populations**
- **Section D: Drug utilization in specific therapeutic areas**
- **Section E: Determinants of drug utilization**
- **Section F: Adherence and drug utilization research**
- **Section G: The role of drug utilization within the field of pharmacoepidemiology**
- **Section H: Assessment and improvement of the quality of medicine use**

Section A on **comparative drug utilization research** explores studies comparing drug utilization patterns across geographical areas, between health settings (primary care practices and hospitals) and over time (e.g. exploring seasonality in drug use). Comparative drug utilization research relates to theories of benchmarking (i.e. the process of establishing best practices through comparison of performance). There are multiple, diverse reasons for the variation in clinical practice, reflecting personal, organizational and system levels. The desire to compare different countries was one of the main reasons for the development of drug utilization research. In addition to comparisons across geographical areas, comparative drug utilization research may be conducted across different health care settings or different populations. Examples of comparative studies exploring drug utilization in relation to various patient, prescriber and health care system characteristics are also presented.

Section B on **drug utilization and health policy** focuses on how policymakers and other key stakeholders shape pharmaceutical policy and how drug utilization research contributes to this process. Health policy has been defined as the conscious attempt by public officials or executives entrusted with public funds, including those working in health authorities, health insurance agencies or managed care organizations, to achieve certain objectives through a set of laws, rules, procedures and incentives [60]. Pharmaceutical policy debates issues of unmet need, access to medicines, pricing, cost containment, irrational use of medicines, innovation and services provision. This is growing in importance, given ever-increasing pressure on resources through changes in demographics, the continued launch of new premium-priced drugs to address areas of unmet need and financial concerns in a number of countries.

Section C on **drug utilization in specific populations** describes drug utilization research in three distinct populations across the life span, from conception until the end of life. There is a specific focus on pregnancy, children and the elderly, since drug use in these groups is often associated with considerable risks and inappropriate use. These chapters give an overview of frequently used medications in these populations. Specific methodological issues that have to be considered when assessing medication use in these populations are also discussed.

Section D on **drug utilization in specific therapeutic areas** explores drug utilization studies of antibiotics as an example of acute therapy, cardiovascular and neuropsychiatric medicines as examples of medicines for chronic use, and biologicals and cancer drugs as emerging topics in drug utilization research. The section includes discussions around the main directions of drug utilization research and provides examples of drug utilization studies conducted in the given therapeutic areas.

Section E on **determinants of drug utilization** describes the key influences on utilization, starting with health systems/policies, followed by prescriber perspectives (exploring the role of the prescribers and factors influencing their behaviour) and ending with a chapter on patient perspectives. The use of medicines is determined by a complex range of interrelated factors, including individual patients’ beliefs in medicines, differences in the practices of prescribers/suppliers and health systems/policies and international influences.

Section F on **adherence and drug utilization research** explores recently emerged interest in adherence within the drug utilization domain. Adherence to medicines refers to taking medication as prescribed, starting from prescribing and the initiation of treatment, through the
implementation of the correct dose regimen and finishing with discontinuation. In this section, the use of diverse methodologies and data sources for adherence research is explored and determinants of nonadherence and interventions to improve adherence are discussed.

Section G on the role of drug utilization within the field of pharmacoepidemiology examines the role of drug utilization research in risk management, pharmacovigilance, outcome research and pharmacoconomics. In these areas, drug utilization research expertise contributes to a number of key issues, including drug safety and effectiveness, pharmaceutical expenditure and drug policy strategies. These aspects of drug utilization are described across five chapters, taking into account the views of both the researcher and the regulator.

Finally, Section H on assessment and improvement of the quality of medicine use explores current strategies for assessing and improving medicines use. From an overview of existing quality indicators in a specific conceptual framework, it evolves to describe academic detailing and other interventions already tested for the improvement of prescribing and the implementation plans by which these interventions and quality indicators are put into action. Additionally, behavioural change, key to any attempt to enhance the quality of prescribing and dispensing, is discussed, as is the need to consider a realistic approach to the evaluation of interventions designed to enhance drug utilization.

To summarize, the aim of this book is to provide the reader with a toolkit containing the various methods used within drug utilization research, to give examples of various applications of research and to demonstrate how drug utilization studies help shape health policy and clinical practice internationally.